相关实验视频
Updated: Jun 25, 2025

10:41
Method to Measure Tone of Axial and Proximal Muscle
Published on: December 14, 2011
17.6K
在帕金森病中治疗轴立姿势异常的肉毒毒素:系统性审查
Marialuisa Gandolfi1,2,3, Carlo Alberto Artusi4,5, Gabriele Imbalzano4,5
1Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.
Toxins
|May 24, 2024
概括
肉毒毒素 (BoNT) 在帕金森病,尤其是皮萨综合征的轴性姿势异常 (APA) 中显示出有前途. 早期康复对于管理这些残疾症状至关重要.
科学领域:
- 神经学 神经学
- 运动障碍 运动障碍
- 康复医学 康复医学 康复医学
背景情况:
- 轴姿势异常 (APA) 是帕金森病 (PD) 和非典型帕金森症的常见,致残和耐治疗并发症.
- 这些症状往往被低估,加剧了患者的残疾,尽管诊断和病理生理学的进步.
- 对APA的有效管理策略仍然是一个重大的临床挑战.
研究的目的:
- 系统地审查毒素 (BoNT) 治疗的疗效,包括康复和没有康复,用于PD患者的APA.
- 确定研究缺口,特别是关于前科和组合疗法方法.
主要方法:
- 在MEDLINE (PubMed),Web of Science和SCOPUS数据库中进行系统的文献搜索.
- 包括1087个检索记录中的16项研究,重点是针对坎普托科尔米亚和皮萨综合征的BoNT.
- 对治疗策略的分析,包括电肌学 (EMG) 指导和超声波增强注射.
主要成果:
- 毒素是对坎普托科尔米亚和皮萨综合征的主要研究治疗方法,主要使用观察方法.
- 皮萨综合征患者在APA和BoNT的疼痛中显示出一致的改善.
- 有限的研究存在于联合BoNT和康复;安特科利斯仍然是研究不足的.
结论:
- 熟练的临床医生对精确选择的患者进行精确的,以电肌图为指导的BoNT注射到过度活跃的肌肉中.
- 早期和综合康复对于有效管理APA至关重要.
- 涉及专家团队的多学科方法对于PD中全面的APA管理至关重要.
相关概念视频
Parkinson's Disease: Treatment
261
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
261
Parkinson's Disease: Overview
528
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
528
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
674
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
674
Skeletal Muscle Relaxants: Therapeutic Uses
480
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
480
Classification of Skeletal Muscle Relaxants
2.5K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.5K
Centrally Acting Muscle Relaxants: Therapeutic Uses
668
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
668

